Tracking the Real-World impact of a new cholesterol shot
NCT ID NCT05399992
Summary
This study is observing how well a cholesterol-lowering injection called inclisiran works for people in their regular doctor's care. It will follow about 850 adults with high cholesterol for up to two years to see how much their 'bad' cholesterol drops and how consistently they get their shots. The goal is to understand the drug's real-world effectiveness and how easy it is for patients to stick with the treatment schedule.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Feldkirch, 6807, Austria
-
Novartis Investigative Site
Graz, 8036, Austria
-
Novartis Investigative Site
Linz, 4021, Austria
-
Novartis Investigative Site
Sankt Veit im Pongau, 5621, Austria
-
Novartis Investigative Site
Vienna, 1090, Austria
-
Novartis Investigative Site
Vienna, 1180, Austria
-
Novartis Investigative Site
Shenzhen, Guangdong, 518000, China
-
Novartis Investigative Site
Holon, Gush Dan, 5845997, Israel
-
Novartis Investigative Site
Petah Tikva, 4941492, Israel
-
Novartis Investigative Site
Tel Aviv, 6801296, Israel
-
Novartis Investigative Site
Kuala Lumpur, Kuala Lumpur, 50470, Malaysia
-
Novartis Investigative Site
Kuala Lumpur, 50400, Malaysia
-
Novartis Investigative Site
Riyadh, Saudi, 11643, Saudi Arabia
-
Novartis Investigative Site
Jeddah, 23311, Saudi Arabia
-
Novartis Investigative Site
Tabuk, 47512, Saudi Arabia
-
Novartis Investigative Site
Fribourg, CH, 1708, Switzerland
-
Novartis Investigative Site
Basel, 4031, Switzerland
-
Novartis Investigative Site
Geneva, 1211, Switzerland
-
Novartis Investigative Site
Lausanne, 1011, Switzerland
-
Novartis Investigative Site
Olten, 4600, Switzerland
-
Novartis Investigative Site
Sankt Gallen, 9007, Switzerland
-
Novartis Investigative Site
Zurich, 8032, Switzerland
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
Novartis Investigative Site
Abu Dhabi, Abu Dhabi Emirate, 00000, United Arab Emirates
-
Novartis Investigative Site
Dubai, United Arab Emirates, 7272, United Arab Emirates
-
Novartis Investigative Site
Abu Dhabi, United Arab Emirates
-
Novartis Investigative Site
Al Ain City, United Arab Emirates
-
Novartis Investigative Site
Dubai, United Arab Emirates
-
Novartis Investigative Site
High Wycombe, Buckinghamshire, HP11 2TR, United Kingdom
-
Novartis Investigative Site
Louth, Lincolnshire, LN11 7QU, United Kingdom
-
Novartis Investigative Site
Sunderland, Tyne and Wear, SR4 7TP, United Kingdom
-
Novartis Investigative Site
Belfast, BT16 1RH, United Kingdom
-
Novartis Investigative Site
Bromwich, B71 4HJ, United Kingdom
-
Novartis Investigative Site
Burton-on-Trent, DE13 0RB, United Kingdom
-
Novartis Investigative Site
Cardiff, CF14 4XW, United Kingdom
-
Novartis Investigative Site
Hull, HU3 2RW, United Kingdom
-
Novartis Investigative Site
Lancaster, LA1 4RP, United Kingdom
-
Novartis Investigative Site
Liverpool, L7 8XP, United Kingdom
-
Novartis Investigative Site
London, NW3 2QG, United Kingdom
-
Novartis Investigative Site
Middlesex, UB9 6JH, United Kingdom
Conditions
Explore the condition pages connected to this study.